OBJECTIVES-To explore the relationship between level and type of comorbidity and guideline-concordant care for early-stage breast cancer.
Kentucky, Louisiana, Minnesota, North Carolina, Wisconsin). Human subjects committee approval was obtained from each participating institution. Re-abstraction of hospital and physician office records supplemented registry data on initial course of treatment. Additional data on adjuvant therapy and comorbidities were obtained from physicians and outpatient facilities. Cases were randomly selected across strata of race and ethnicity and state-specific factors (e.g., Appalachian vs non-Appalachian region, type of facility, and patient volume of the facility) and oversampled for racial and ethnic minorities in some states. Cases from Veterans Affairs hospitals and identified solely from death certificates or autopsies were excluded.
Study Sample
The initial sample included 9,142 women with breast cancer. Exclusion criteria were missing stage (n = 1,601); metastatic cancer (n = 358); missing tumor size, if nodal status negative or hormone receptor status missing (n = 94); missing nodal status (n = 185); no primary breast tumor (T0, n = 22); and missing hormone receptor status and did not receive ET (n = 418). Cases in which RT (n = 105), ET (n = 257), and CTX (n = 218) and breast (n = 15) or node (n = 14) surgeries were unknown were also excluded. This excluded 2,703 women, leaving a final sample of 6,439. Characteristics of included women were different from those excluded with regard to payor (more Medicare, less Medicaid), race (more blacks, fewer Hispanics) and stage (more Stage 0, fewer Stage 2 and 3).
Hormone receptor (estrogen (ER) and progesterone (PR) status was defined as positive (ER+ or PR+, or both), negative (ER− and PR−), or unknown. Human epidermal growth factor receptor 2 (HER2) status was defined as positive (3 + according to immunohistochemistry (IHC) or amplified using fluorescent in situ hybridization (FISH)), negative (0 or 1 + according to IHC or 2 + according to IHC and not amplified using FISH), or unknown, although HER2 status was not consistently recorded for early-stage breast cancer cases in 2004.
Outcomes
The primary outcome was receipt of guideline-concordant care or not. Guideline-concordant breast cancer treatment was defined based on tumor size, nodal status, and hormone receptor status, similar to previous work. 13 For each of 10 categories, National Comprehensive Cancer Network 16 and St. Gallen Conference 17 guidelines were consulted to create management requirements, which included components of surgery (BCS or mastectomy), adjuvant RT (before, during, or after surgery), lymph node surgery (LN), CTX, and ET. Minimum acceptable components of therapy for each group are as follows:
Group A (ductal carcinoma in situ (DCIS)), BCS with RT or mastectomy Group B (T1a-b N0), BCS with RT and LN or mastectomy and LN Group C+ (T1cN0, >1 cm, ER with PR+), BCS with RT or mastectomy, LN, ET, and CTX if younger than 70
Group D− (T2N0, ER with PR−), BCS with RT or mastectomy, LN, and CTX Group E+ (T1-3 N1-3 or T3N0, and ER with PR+), BCS with RT or mastectomy,  LN, ET, and CTX   Group E− (T1-3N1-3 or T3N0 and ER with PR−), BCS with RT or mastectomy, LN,  and CTX   Group F+ (T4NX and ER with PR+) , mastectomy, LN, ET, and CXT Group F− (T4NX and ER with PR−), mastectomy, LN, and CTX Receipt of more than guideline management was considered guideline concordant.
Comorbidity
The ACE-27, 10 a robust, validated, chart-based instrument developed specifically for individuals with cancer, was used. The index includes 26 conditions relevant to cancer therapy choice and outcome, and their severity, measured according to three levels of decompensation. After training using a tested and validated Internet-based program, abstractors reviewed records and assigned comorbidity categories and level of decompensation based on diagnoses, medical history, and laboratory and clinical tests. 10, 18 Comorbidities present at or before diagnosis were included; complications of treatment were excluded. An overall comorbidity index (none, low, moderate, or severe) was assigned to each participant based on the comorbidity with the highest level of decompensation. Severe level of decompensation for the overall index was assigned in cases in which there was a moderate level of decompensation of two or more comorbidities in different body systems (e.g., cardiovascular and nervous), even if none were severe. 18 The 26 categories were also mapped into 12 groups, based on organ system: cardiovascular disease (myocardial infarction, coronary artery disease, congestive heart failure, arrhythmia, hypertension, venous disease, peripheral artery disease), respiratory diseases, gastrointestinal diseases (hepatic disease, stomach or intestinal diseases, pancreatic disease), renal disease, diabetes mellitus, nervous system (stroke or cerebrovascular accident, dementia, paralysis, neuromuscular disorders), psychiatric, rheumatological, acquired immunodeficiency syndrome (AIDS), cancer (solid tumor, leukemia, lymphoma) excluding the index cancer, substance abuse (alcohol abuse, illicit drugs), morbid obesity.
Statistical Analysis
Cases were stratified according to overall comorbidity burden (none, minor, moderate, severe). Receipt of guideline-concordant breast cancer care, for each group across the aggregated and disaggregated measures of burden, was compared using chi-square statistics. Similar analyses were conducted for each of the 12 mapped comorbidity categories (as above). Finally, multivariate logistic regressions were estimated using three comorbidity classifications: 26 ACE-27 comorbidity categories (Model 1), 12 collapsed ACE-27 categories (Model 2), and four levels of comorbidity (Model 3). Three models were created to maximally explore specific comorbidities and groups of comorbidities and to study the dose-response relationship overall. With these regressions, the statistics are reported for four age categories (<50, 50-64, 65-74, ≥75) and four racial ethnic groups (white, black, Hispanic, other), because these are factors known to be related to comorbidity and to guideline concordance and control for the 10 stage groups and source of payment. SAS version 9.2 was used throughout the analyses (SAS Institute, Inc., Cary, NC).
RESULTS
The study population was primarily Caucasian (76.0%), with mean age of 58.7 (range 20-99; Table 1 ). ACE comorbidity level was severe in 3.9%, moderate in 9.9%, mild in 42.0%, and none in 44.3%. The most common comorbidities were cardiovascular disease (n = 2,952, 45.8%), diabetes mellitus (n = 802, 12.5%), morbid obesity (n = 534, 8.3%), psychiatric disease (n = 381, 5.9%), and respiratory disease (n = 380, 5.9%).
Care was guideline concordant in two-thirds of participants (69.5% without comorbidity, 59.5% with). Surgery was BCS in 57.9% and mastectomy in 40.9%; 82.7% had had a LN assessment. RT occurred in 80.6% of participants who underwent BCS. CTX was delivered to 38.9%. ET was used in 54.7% overall and in 71% of women with ER+ or PR+ tumors or both. Table 2 shows the unadjusted rate of guideline-concordant care according to stage and comorbidity categories. Guideline concordance varied between stage groups (unreported chi-square P < .001), and level of comorbidity (P < .05). Concordance was inversely proportional to comorbidity burden: 69.5% for none, 61.4% for minor, 58.0% for moderate, and 42.7% for severe, although this inverse relationship is statistically significant for only some individual stage groups (e.g., individuals with DCIS (A)). Table 2 also shows statistically significant relationships between individual comorbidity categories and guideline-concordant treatment for a number of conditions, including cardiovascular disease, end-stage renal disease, diabetes mellitus, nervous system disorders, psychiatric disorders, and rheumatological disease. For all but psychiatric disorders, the presence of the condition was always associated with less-concordant care. In some cases, such as diabetes mellitus and nervous system disorders, there is a clear inverse relationship between severity and concordance.
Any comorbidity, versus none, was associated with less-guideline-concordant care (P < .05) in four stage strata (stage I, tumor >1 cm and hormone receptor positive (C+), 26.1% vs 37.7%; stage IIA and hormone receptor positive (D+), 29.5% vs 53.2%; stage IIA and hormone receptor negative (D−), 53.1% vs 75%; and stage IIB or III and hormone receptor positive (E+), 56.8% vs 67.5%) and overall (59.5% vs 69.5%). The presence of comorbidity did not significantly affect the rate of guideline-concordant care for DCIS or less than 1 cm, node-negative cancers, for which only local therapy met guideline concordance. Few cases of higher-stage cancer may have limited the ability to find significant differences in rates of guideline-concordant care according to comorbidity level.
The effect of specific diagnosis and severity on receipt of guideline-concordant care was examined (Table 2) . In unadjusted analyses, comparing any comorbidity with none, receipt of guideline-concordant care was less likely (P < .05) with cardiovascular diseases (58% vs 69%), renal disease (37% vs 64%), diabetes mellitus (54% vs 65%), nervous system disease (35% vs 65%), and rheumatological disease (49% vs 64%). Delivery of guidelineconcordant care was more likely (univariate P < .05) with psychiatric illness (70% vs 63%).
In univariate analysis, with comorbidity categorized according to level of severity, significant differences in guideline-concordant care (P < .05) were found for diabetes mellitus and for cardiovascular, renal, and nervous system diseases. For AIDS, other cancers, substance abuse, and obesity, small numbers limited detection of a dose-response relationship. Table 3 shows results of multivariate analyses using three models. In Model 1, less guideline concordance was associated with dementia (OR = 0.45, 95% CI = 0.24-0.83), older age, and black race (vs white OR = 0.87, 95% CI = 0.76-0.99) and higher likelihood of guideline concordance with hypertension (OR = 1.15, 95% CI = 1.01-1.30). In Model 2, less guideline concordance was associated with renal system disease (OR = 0.57, 95% CI = 0.33-0.99), nervous system disease (OR = 0.62, 95% CI = 0.47-0.82), and older age. In Model 3, less guideline concordance was associated with severe comorbidity (OR = 0.67, 95% CI = 0.51-0.89), older age, and black race.
DISCUSSION
Using this large, retrospective database, with systematically collected, detailed information about comorbid diagnoses and tumor registry and record-based information about multicomponent breast cancer management, the authors of this study confirmed that higher comorbidity is associated with a lower rate of multidisciplinary guideline-concordant care. Older age and black race also predicted less guideline concordance. 19, 20 This adds to the literature by exploring the effect of specific comorbid diagnoses on receipt of guidelineconcordant breast cancer care. In unadjusted analyses, guideline concordance was lower with cardiovascular, renal, nervous system, and rheumatological diseases and diabetes mellitus; this held true in adjusted analyses for renal and nervous system diseases. With regard to specific diagnoses, dementia was associated with less-guideline-concordant care whereas hypertension was associated with small, but statistically significantly greater guideline concordance.
It may be that a diagnosis of hypertension implies more access to health care and, therefore, greater likelihood of guideline concordance and better outcomes. Individuals with a diagnosis of hypertension are likely to receive antihypertensive medication and are more likely to receive guideline-concordant care, either of which might improve outcomes. Thus, use of guideline-concordant breast cancer care may have confounded previous reports that antihypertensive use improves breast cancer prognosis. 7, [21] [22] [23] Future research studying the effects of comorbid diagnoses and their treatment on breast cancer outcome should include an assessment of guideline-concordant cancer treatment.
In general, higher comorbidity burden led to less guideline-concordant care, which may be justified, given the known inverse relationship between comorbidity and life expectancy 24 and higher financial or quality-of-life burdens, especially in those with high comorbidity burden. Comorbidity may decrease the benefits or increase the risk of certain components of care. For instance, the current study found that individuals with stage IIA disease (T2N0), regardless of hormone receptor status, and stage IIB and III disease with hormone receptorpositive disease, in which the absolute benefit of adding chemotherapy is small, were significantly less likely to receive guideline-concordant care.
Strengths of this study include the large, geographically diverse database, with tumor registry data augmented with chart abstraction, and use of the ACE-27 comorbidity measure. Record re-abstraction enabled capture of detailed information about tumor characteristics, treatment, and comorbid conditions. Whereas most studies of comorbidity were limited to older adults with Medicare, this study included individuals aged 20-99. Large sample size and availability of well-defined variables pertaining to demographic, participant, tumor, and treatment characteristics facilitated study of multicomponent management. Whereas other studies have primarily focused on single treatment components, the rich database allowed study of multicomponent, coordinated care. Use of the ACE-27, a robust, validated, chartbased instrument, developed specifically for individuals with cancer to study presence and severity of comorbidity, is a tremendous strength of the study. 10 Other studies have used less-powerful measures of comorbidity. 1, 3, 8, 9 The widely used Charlson Comorbidity Index 25, 26 can be used with administrative databases but includes fewer comorbidities and no information about disease severity. The Cumulative Illness Rating Scale, perhaps the most-comprehensive index, requires detail only available in prospective studies. 27 A claimsbased version of the ACE has been proposed. 28 Detailed information from the ACE-27 also allowed associations with specific comorbid diagnoses, rather than only a summary score of comorbidity, to be explored. 5 There are limitations to this study. As a retrospective study, what was recorded in the medical record, which is a poor source of information about physician and individual decision-making, actual referrals, and patient adherence, limited it. Lack of record review from each involved physician may have led to missed care components, but the abstractors sought records from hospital and physician offices. Inclusion criteria for the analysis excluded approximately 25% of the database and may limit external validity of the findings. Small numbers in some subcategories limited power. Last, the study was structured to detect treatment meeting minimum standards; because less than guideline care is known to be associated with worse outcomes, it was felt that overclassification in this direction was acceptable.
In summary, this study found that greater comorbidity burden is associated with a lower rate of guideline-concordant multidisciplinary care. The noted association between guideline care and hypertension is worthy of further study. Because less than guideline-concordant care for breast cancer, regardless of age or race, leads to inferior outcomes, 29, 30 where possible in studies of cancer outcome, guideline concordance should be included in analyses. a Diseases included myocardial infarction, angina pectoris or coronary artery disease, congestive heart failure, arrhythmias, hypertension, venous disease, peripheral arterial disease, respiratory system disease, hepatic disease, stomach or intestinal disease, pancreatic disease, end-stage renal disease, diabetes mellitus, stroke, dementia, paralysis, neuromuscular disease, psychiatric disorder, rheumatologic disease, acquired immunodeficiency syndrome, solid tumor including melanoma, leukemia or myeloma, lymphoma, alcohol abuse, illicit drugs, obesity.
b Percent who received adjuvant RT among those who had BCS. b Observations excluded (n = 231) for missing payer or race, also omitted metastatic, missing stage, if both PR and ER receptors missing, and if tumor size missing and nodes less than N1.
c Statistically significant, three levels of comorbidity and none, chi-square, P < .05. ACE = Adult Comorbidity Evaluation; AIDS = acquired immunodeficiency syndrome.
